ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) shares traded up 1.3% during trading on Friday . The stock traded as high as $6.08 and last traded at $6.08. 818 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 3,468 shares. The stock had previously closed at $6.00.
ProMIS Neurosciences Price Performance
The firm’s 50 day moving average is $5.81. The firm has a market cap of $52.16 million, a PE ratio of -3.32 and a beta of 0.64.
Institutional Trading of ProMIS Neurosciences
A hedge fund recently bought a new stake in ProMIS Neurosciences stock. Northeast Financial Consultants Inc purchased a new position in ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $613,000. Northeast Financial Consultants Inc owned 1.17% of ProMIS Neurosciences at the end of the most recent reporting period. Institutional investors own 0.14% of the company’s stock.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (PMN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.